Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOTAL THERAPY for Untreated or Minimally Treated Multiple Myeloma
NCT00580372Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Aug 2002
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of vincristine sulfate liposome injection, pegylated liposomal doxorubicin, dexamethasone, cyclophosphamide, etoposide in multiple myeloma (MM), sponsored by University of Arkansas. Started Aug 2002; status: completed.
02
Drugs
vincristine sulfate liposome injectionpegylated liposomal doxorubicindexamethasonecyclophosphamideetoposide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00580372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00580372.